Zobrazeno 1 - 10
of 227
pro vyhledávání: '"Hugh S. Mason"'
Autor:
Andrew G. Diamos, Mary D. Pardhe, Melissa H. Bergeman, Aigerim S. Kamzina, Michelle P. DiPalma, Sara Aman, Artemio Chaves, Kenneth Lowe, Jacquelyn Kilbourne, Ian B. Hogue, Hugh S. Mason
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionIt has been known for over half a century that mixing an antigen with its cognate antibody in an immune complex (IC) can enhance antigen immunogenicity. However, many ICs produce inconsistent immune responses, and the use of ICs in the de
Externí odkaz:
https://doaj.org/article/9d33a692d17b4c849b36e64b619e6dfd
Autor:
Ki-Beom Moon, Jae-Heung Jeon, Hyukjun Choi, Ji-Sun Park, Su-Jin Park, Hyo-Jun Lee, Jeong Mee Park, Hye Sun Cho, Jae Sun Moon, Hyunwoo Oh, Sebyung Kang, Hugh S. Mason, Suk-Yoon Kwon, Hyun-Soon Kim
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-7 (2022)
Abstract The pandemic of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused a public health emergency, and research on the development of various types of vaccines is rapidly progressing at an unprecedented development speed inte
Externí odkaz:
https://doaj.org/article/0603aea4c9b647d68a4daa4c22cc18fc
Autor:
Andrew G. Diamos, Mary D. Pardhe, Haiyan Sun, Joseph G. L. Hunter, Jacquelyn Kilbourne, Qiang Chen, Hugh S. Mason
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Therapeutics based on fusing a protein of interest to the IgG Fc domain have been enormously successful, though fewer studies have investigated the vaccine potential of IgG fusions. In this study, we systematically compared the key properties of seve
Externí odkaz:
https://doaj.org/article/acc80e1abe3f4a6dbd055da1af84faa3
Autor:
Andrew G. Diamos, Joseph G. L. Hunter, Mary D. Pardhe, Sun H. Rosenthal, Haiyan Sun, Bonnie C. Foster, Michelle P. DiPalma, Qiang Chen, Hugh S. Mason
Publikováno v:
Frontiers in Bioengineering and Biotechnology, Vol 7 (2020)
Biopharmaceuticals are a large and fast-growing sector of the total pharmaceutical market with antibody-based therapeutics accounting for over 100 billion USD in sales yearly. Mammalian cells are traditionally used for monoclonal antibody production,
Externí odkaz:
https://doaj.org/article/7dbedbc40996457faf93f23e818853cf
Autor:
Joseph G.L. Hunter, Shyra Wilde, Amanda M. Tafoya, Jamie Horsman, Miranda Yousif, Andrew G. Diamos, Kenneth L. Roland, Hugh S. Mason
Publikováno v:
PeerJ, Vol 7, p e6600 (2019)
Background Necrotic enteritis (NE) is caused by type A strains of the bacterium Clostridium perfringens. Total global economic losses to the poultry industry due to NE is estimated to be over two billion dollars annually. Traditionally, NE has been e
Externí odkaz:
https://doaj.org/article/2df716c266204cd2a872ee891898d695
Autor:
Andrew G. Diamos, Hugh S. Mason
Publikováno v:
Frontiers in Plant Science, Vol 9 (2019)
Plants are a promising platform to produce biopharmaceutical proteins, however, the toxic nature of some proteins inhibits their accumulation. We previously created a replicating geminiviral expression system based on bean yellow dwarf virus (BeYDV)
Externí odkaz:
https://doaj.org/article/e26793668b6441138ece4e1b97abb0b2
Publikováno v:
Frontiers in Plant Science, Vol 7 (2016)
We previously reported a recombinant protein production system based on a geminivirus replicon that yields high levels of vaccine antigens and monoclonal antibodies in plants. The bean yellow dwarf virus (BeYDV) replicon generates massive amounts of
Externí odkaz:
https://doaj.org/article/e1d1f75a55b74ef0881b6ed0cd1c7434
Publikováno v:
Journal of General Virology. 100:1038-1051
Geminiviruses are a group of small plant viruses responsible for devastating crop damage worldwide. The emergence of agricultural diseases caused by geminiviruses is attributed in part to their high rates of recombination, leading to complementary fu
Autor:
Aigerim S, Kamzina, Michelle P, DiPalma, Joseph G L, Hunter, Andrew G, Diamos, Boyd, Armer, Tsafrir S, Mor, Hugh S, Mason
Publikováno v:
Journal of visualized experiments : JoVE. (167)
High demand for antibodies as therapeutic interventions for various infectious, metabolic, autoimmune, neoplastic, and other diseases creates a growing need in developing efficient methods for recombinant antibody production. As of 2019, there were m
Autor:
Hugh S. Mason, Tsafrir S. Mor, Boyd Armer, Andrew G. Diamos, Joseph G. L. Hunter, Michelle P. DiPalma, Aigerim S. Kamzina
Publikováno v:
Journal of Visualized Experiments.